CICATRENE ® is a drug based on Neomycin sulfate + Bacitracin zinc + Glycine, Cysteine and Threonine
THERAPEUTIC GROUP: Antibiotics and chemotherapeutic drugs in combination
IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects
Indications CICATRENE ® Neomycin + Bacitracin + Glycine, Cysteine and Threonine
CICATRENE ® is used in the clinical field in the treatment of superficial skin infections sustained by microorganisms sensitive to neomycin and bacitracin or in superficial infectious risk lesions.
Mechanism of action CYATRENE ® Neomycin + Bacitracin + Glycine, Cysteine and Threonine
CICATRENE ®, a drug widely used both in the clinical and as a self-medication tool, is a product capable of combining active ingredients with marked microbicide activity, even amino acids, capable of stimulating fibroblastic proliferation, shortening the repair time of the skin lesion.
This activity is facilitated by the possibility of the various topically applied active ingredients to concentrate in the center, thus representing a ready-to-use substrate for the various biological elements present.
The therapeutic activity of CICATRENE ® is therefore guaranteed by the presence of:
- Neomycin, an antibiotic belonging to the category of aminoglycosides capable of exercising bacteriostatic and bactericidal action by inhibiting the 30S ribosomal subunit and blocking protein synthesis. The formation of aberrant proteins in addition to compromising the normal metabolic activity of the microorganism, is able to damage the membrane and the bacterial wall, determining its lysis.
- Bacitracin, a polypeptide antibiotic with direct activity mainly against Gram positive organisms capable of inhibiting some enzymatic steps necessary for the synthesis of peptidoglycan, thus compromising the synthesis of the bacterial wall.
- Glycine, Cysteine and threonine, amino acids particularly used by cells in active replication, fundamental for fibroblasts in order to optimize the synthesis of new matrix, thus ensuring a rapid recovery of the histological characteristics of the damaged tissue.
Studies carried out and clinical efficacy
1 NEOMYCIN IN BURNED PATIENTS
Am J Clin Dermatol. 2002; 3 (8): 529-34.
Important review that demonstrates the efficacy of neomycin taken for topical use in improving the clinical conditions of burn patients, allowing a rapid regression of skin lesions and protecting the skin from bacterial infections.
2 . NEOMYCIN OTOTOXICITY
J Laryngol Otol. 2005 Jan; 119 (1): 48-50.
Yet another study that demonstrates how neomycin, as an aminoglycoside, has a potential ototoxic role, especially in all potentially predisposed patients. For this reason we do not recommend the application of this antibiotic at the level of the external ear and the auditory canal.
3.IPERSENSITIVITY TO NEOMYCIN
Pharmacoepidemiol Drug Saf. 2005 Oct; 14 (10): 725-33.
Interesting epidemiological study conducted on over 47 thousand patients which demonstrates how neomycin can be particularly sensitizing and sometimes responsible for potentially dangerous adverse reactions.
Method of use and dosage
CICATRENE ®
Cream and powder for skin use consisting of 3, 300 IU of neomycin sulfate, 250 IU of bacitracin zinc, 10 mg of L-Glycine, 2 mg of L-Cysteine and 1 mg of L-threonine per gram of product.
It is recommended to apply CICATRENE ® only after a thorough cleansing of the injured region.
Applying a thin layer of cream or the appropriate amount of powder twice a day is able to guarantee a speedy recovery of the wound in a few days, avoiding the overlap of bacterial infections.
Warnings CICATRENE ® Neomycin + Bacitracin + Glycine, Cysteine and Threonine
Although the use of CICATRENE ® is generally safe and has no clinically relevant side effects, prolonged use of the medicine could lead to the appearance of local adverse reactions.
The possible appearance of the aforementioned effects should alarm the patient, who after consulting his doctor, could consider the possibility of suspending the therapy in progress.
The application of the drug on the mucous membranes or on the conjunctiva, on particularly extensive regions and on the deeply damaged skin could facilitate the systemic absorption of the antibiotics contained in it, exposing the patient to side effects sometimes serious as nephrous and ototoxicity.
Prolonged and inadequate use of the product could facilitate the formation of strains resistant to common antibiotic therapy, aggravating the patient's clinical picture.
PREGNANCY AND BREASTFEEDING
The use of CICATRENE ® during pregnancy and in the subsequent period of breastfeeding should be carried out exclusively in cases of real need and always under strict medical supervision, avoiding all possible conditions that can facilitate the systemic absorption of the active ingredients.
Interactions
At the moment active ingredients capable of altering the therapeutic properties and safety profile of CICATRENE ® are not known.
However, due to the possible nephrotoxic and ototoxic effects, the concomitant administration of other aminoglycosides, especially by systemic route, is not recommended.
Contraindications CICATRENE ® Neomycin + Bacitracin + Glycine, Cysteinee Threonine
The use of CICATRENE ® is contraindicated in case of hypersensitivity to the active ingredient and its excipients.
Also remember to avoid contact of the drug with the mucous membranes and conjunctiva.
Undesirable effects - Side effects
The use of CICATRENE ® is generally well tolerated and has no clinically relevant side effects.
This safety, guaranteed by the topical use of the medicine and the low systemic absorption of the active ingredients, does not expose the patient to particularly significant risks.
However, local hypersensitivity reactions with possible overlapping of bacterial infections sustained by microorganisms resistant to neomycin and bacitracin could occur following prolonged use of the drug.
Note
CICATRENE ® is not subject to mandatory medical prescription.
